MedPath

The clinical significance of acid rebound: Symptoms of reflux after 8 weeks of PPI treatment in patients with functional dyspepsia.

Conditions
Acid-Rebound Hypersecretion and Functional dyspepsia
MedDRA version: 13.1Level: LLTClassification code 10064536Term: Functional dyspepsiaSystem Organ Class: 10017947 - Gastrointestinal disorders
Registration Number
EUCTR2011-000059-17-DK
Lead Sponsor
Koege Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
Not specified
Inclusion Criteria

18 years +
Symptoms of dyspepsia, which GP consider would benefit from PPI treatment.
Access to internet.

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Signs of severe pathology (extreme weight loss ect.)
Symptoms of GORD four weeks before enrolment, according to the Montreal definition.
Abnormal pH profile prior to enrolment or at screening.
Treatment with PPI or H2-blockers on a regular basis the last year before enrolment
Previous surgery on esophagus, stomach or duodenum
Use of NSAIDs, antacids, anti-depressives and other analgesics on a regular basis
Potential language problems in understanding information and registering symptoms
Pregnancy or breast feeding
Other diseases which can interfere with the symptom registration (severe congestive heart disease, malignant disease, schizophrenia ect.).
No access to internet.

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath